Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Efavirenz and SHR1459 in Healthy Subjects
NCT05560360Phase 1Completed
- Sponsor
- Hengrui
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edralbrutinib in B-cell lymphoma (BCL), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from Time 0 to Last Measurable Concentration and 1 more. Started Nov 2022; status: completed.
02
Drugs
edralbrutinib
03
Conditions
B-cell lymphoma (BCL)
Beyond the preview
Go deeper on NCT05560360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05560360.